Pyroptosis induced by GSDMD and NLRC4 in high-grade gliomas can promote the progression of gliomas and enhance the sensitivity of these tumors to immune checkpoint therapy by recruiting immune cells (127). The gene discussed is GSDMD; the disease is central nervous system cancer.